Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Paula Marlton, Umberto Vitolo, Ola Linden, John Seymour, Michael Crump, Bertrand Coiffier, Alessandro Pulsoni, Andrew Belch, Erika Lerch, Eva Kimby, Kristina Arnljots, Elisabeth Wassner, Myriam Mendila

Blood (2007) 110 (11): 645.

https://doi.org/10.1182/blood.V110.11.645.645

Published: 2007

Journal Articles

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Frank Morschhausser, Martin Wolf, John Seymour, Herve Tilly, Michael Pfreundschuh, Hanneke Kluin-Nelemans, John Raemaekers, Mars B. van’t Veer, Noel Milpied, Guillaume Cartron, Antonio Pezzutto, Andrew Spencer, Christelle Darstein, Donald Thornton, Martin Dreyling, Felix Reyes

Blood (2006) 108 (11): 2450.

https://doi.org/10.1182/blood.V108.11.2450.2450

Published: 2006

Journal Articles

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8 + T-cell function in Hodgkin lymphoma patients

Maher K. Gandhi, Eleanore Lambley, Jaikumar Duraiswamy, Ujjwal Dua, Corey Smith, Suzanne Elliott, Devinder Gill, Paula Marlton, John Seymour, Rajiv Khanna

Blood (2006) 108 (7): 2280–2289.

https://doi.org/10.1182/blood-2006-04-015164

Published: 2006

Journal Articles

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, PhD, Roswitha Forstpointner, PhD, Martin Dreyling, PhD, Martin Gramatzki, PhD, Hans-Peter Böck, MD, Mathias Hänel, MD, John Seymour, MD, Manfred Planker, MD, Ulrich Dührsen, PhD, Klaus Wilms, PhD, Martin Clemens, PhD, Wolf-Dieter Ludwig, MD, Hannes Wandt, MD, Rita Pasold, MD, Michael Unterhalt, MD

Blood (2005) 106 (11): 920.

https://doi.org/10.1182/blood.V106.11.920.920

Published: 2005

Journal Articles

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg

Blood (2005) 106 (11): 164.

https://doi.org/10.1182/blood.V106.11.164.164

Published: 2005

NARROW

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8 + T-cell function in Hodgkin lymphoma patients

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Email alerts

ASH Publications

American Society of Hematology

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8 + T-cell function in Hodgkin lymphoma patients

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only